Solid Tumors Clinical Trials

45 studies are recruiting for solid tumors in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

   The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors, including rare BRAF V600E…

   Stage

   Phase 2

   Ages

   8 and older

   Site

   Precision NextGen Oncology & Research Center, Beverly Hills, California

   Locations

   70 in total

   Run by

   Fore Biotherapeutics

   See if you can join NCT05503797 on ClinicalTrials.gov

2. A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

   To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Angeles Clinic and Research Institute, Los Angeles, California

   Locations

   39 in total

   Run by

   Incyte Corporation

   See if you can join NCT05836324 on ClinicalTrials.gov

3. Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors

   The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Zai Lab Site 02003, Los Angeles, California

   Locations

   8 in total

   Run by

   Zai Lab (Shanghai) Co., Ltd.

   See if you can join NCT07374848 on ClinicalTrials.gov

4. A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

   This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic Hospital, Phoenix, Arizona

   Locations

   34 in total

   Run by

   Incyte Corporation

   See if you can join NCT06179160 on ClinicalTrials.gov

5. Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid Tumors

   To study possible biomarkers that may be related to how SAR444881 works (either alone or when combined with cemiplimab) in participants with solid tumors.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Md Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06651593 on ClinicalTrials.gov

6. A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)

   The goal of this study is to assess the safety and tolerability of Mocertatug Rezetecan . The study will also see how the levels of Mo-Rez change over time at different dose amount

   Stage

   Phase 1

   Ages

   18 and older

   Site

   GSK Investigational Site, Birmingham, Alabama

   Locations

   65 in total

   Run by

   GlaxoSmithKline

   See if you can join NCT06431594 on ClinicalTrials.gov

7. JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

   This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Denver, Colorado

   Locations

   15 in total

   Run by

   Jacobio Pharmaceuticals Co., Ltd.

   See if you can join NCT06386146 on ClinicalTrials.gov

8. QTX3034 in Patients With KRAS G12D Mutation

   Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCLA Hematology/Oncology, Los Angeles, California

   Locations

   14 in total

   Run by

   Quanta Therapeutics

   See if you can join NCT06227377 on ClinicalTrials.gov

9. ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

   The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-114 in combination with subcutaneous (SC) amivantamab in patients with advanced or metastatic NSCLC harboring an EGFR exon …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NYU Langone Health, New York, New York

   Locations

   4 in total

   Run by

   ORIC Pharmaceuticals

   See if you can join NCT06816992 on ClinicalTrials.gov

10. A Study of HS-20110 in Participants With Advanced Solid Tumors

    This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    BRCR Medical Center INC, Tamarac, Florida

    Locations

    8 in total

    Run by

    Hansoh BioMedical R&D Company

    See if you can join NCT06892379 on ClinicalTrials.gov

11. Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study

    To collect and analyze specimens that will correlate with clinical outcomes such as acute and late toxicities, quality of life, local control, and survival of patients treated with photon/proton therapy.

    Stage

    Not phased

    Ages

    Any age

    Site

    Mayo Clinic, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT02457962 on ClinicalTrials.gov

12. PumaRx Registry Trial

    This study is a multicenter, observational, post-marketing, registry study designed to track the safety and performance of the RenovoCath® device and assess survival outcomes in patients diagnosed with solid tumors who are treated with localized intra-arterial (IA) delivery of therapeutic agents to…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Baptist Health South Florida, Coral Gables, Florida

    Locations

    3 in total

    Run by

    RenovoRx

    See if you can join NCT06805461 on ClinicalTrials.gov

13. S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

    The primary objective of Part A is to evaluate the safety and tolerability of S-531011 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of S-531011 with or without pembrolizumab. The primary objective of Parts B and C is to evaluate the antitumor activity of …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Florida Health, Gainesville, Florida

    Locations

    8 in total

    Run by

    Shionogi

    See if you can join NCT05101070 on ClinicalTrials.gov

14. A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

    The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion cohorts is randomized.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Exelixis Clinical Site #5, Rogers, Arkansas

    Locations

    9 in total

    Run by

    Exelixis

    See if you can join NCT07123103 on ClinicalTrials.gov

15. DPTX3186 in Wnt Pathway Activated Solid Tumors

    This is a first-in human clinical study of DPTX3186 in subjects with Wnt-pathway activated solid tumors where no other treatments exist. The study will evaluate safety, pharmacokinetics, and initial activity of DPTX3186, as well as explore pharmacodynamic parameters to identify potential biomarkers…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT San Antonio, San Antonio, Texas

    Locations

    2 in total

    Run by

    Dewpoint Therapeutics

    See if you can join NCT07312903 on ClinicalTrials.gov

16. JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

    This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Henry Ford Health System, Detroit, Michigan

    Locations

    8 in total

    Run by

    Jacobio Pharmaceuticals Co., Ltd.

    See if you can join NCT05490472 on ClinicalTrials.gov

17. ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

    This study is to assess the safety and antitumor activity of ABL103 plus pembrolizumab, with or without taxane, in advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Seoul National University Bundang Hospital, Seongnam,

    Locations

    6 in total

    Run by

    ABL Bio, Inc.

    See if you can join NCT07158918 on ClinicalTrials.gov

18. CIBMTR Research Database

    The primary purpose of the Research Database is to have a comprehensive source of observational data that can be used to study HSC transplantation and cellular therapies. A secondary purpose of the Research Database is to have a comprehensive source of data to study marrow toxic injuries. Objective…

    Stage

    Not phased

    Ages

    Any age

    Site

    Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota

    Locations

    2 in total

    Run by

    Center for International Blood and Marrow Transplant Research

    See if you can join NCT01166009 on ClinicalTrials.gov

19. APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

    To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring w…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California

    Locations

    35 in total

    Run by

    Apollomics Inc.

    See if you can join NCT03175224 on ClinicalTrials.gov

20. A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors

    The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0405 in patients with select advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope, Duarte, California

    Locations

    8 in total

    Run by

    Adcentrx Therapeutics

    See if you can join NCT06710379 on ClinicalTrials.gov